151 related articles for article (PubMed ID: 33065614)
1. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
Mukai Y; Yoshida Y; Yoshida T; Kondo T; Inotsume N; Toda T
Ther Drug Monit; 2021 Jun; 43(3):386-393. PubMed ID: 33065614
[TBL] [Abstract][Full Text] [Related]
2. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration.
Mukai Y; Yoshida T; Kondo T; Miura J; Inotsume N; Toda T
Ther Drug Monit; 2022 Dec; 44(6):762-770. PubMed ID: 36372934
[TBL] [Abstract][Full Text] [Related]
4. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
7. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
Miura M; Takahashi N
Rinsho Ketsueki; 2019; 60(9):1140-1147. PubMed ID: 31597837
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
9. Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method.
Verougstraete N; Stove V; Verstraete AG; Stove C
Talanta; 2021 May; 226():122140. PubMed ID: 33676691
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Kralj E; Trontelj J; Pajič T; Kristl A
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
12. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring.
Koller D; Vaitsekhovich V; Mba C; Steegmann JL; Zubiaur P; Abad-Santos F; Wojnicz A
Talanta; 2020 Feb; 208():120450. PubMed ID: 31816725
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.
Zhao D; Long X; Wang J
BMC Pharmacol Toxicol; 2024 Feb; 25(1):20. PubMed ID: 38395895
[TBL] [Abstract][Full Text] [Related]
14. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
Sumimoto T; Nakahara R; Suzuki Y; Tanaka R; Yoshida N; Ogata M; Itoh H
Ther Drug Monit; 2022 Jun; 44(3):419-429. PubMed ID: 34469417
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of valproic acid using a dried plasma spot sampling device.
Li Y; Jiang Y; Cao H; Lin H; Ren W; Huang J; Zhang J
J Mass Spectrom; 2021 Apr; 56(4):e4603. PubMed ID: 33729629
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
17. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
18. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Deb S; Boknäs N; Sjöström C; Tharmakulanathan A; Lotfi K; Ramström S
Cancer Med; 2020 Jan; 9(1):313-323. PubMed ID: 31714021
[TBL] [Abstract][Full Text] [Related]
19. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors.
Verougstraete N; Stove CP
J Pharm Biomed Anal; 2022 Jan; 207():114418. PubMed ID: 34655987
[TBL] [Abstract][Full Text] [Related]
20. Dried Plasma Spots and Oral Fluid as Alternative Matrices for Therapeutic Drug Monitoring of Busulfan: Analytical Method Development and Clinical Evaluation.
Granzotto FCN; da Silva ACC; Lizot LF; Antunes MV; Linden R
Ther Drug Monit; 2021 Jun; 43(3):376-385. PubMed ID: 32960547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
